NecroX-5
Based on 3 publication(s) in Google Scholar
NecroX-5 is a derivative of the NecroX, reduces intracellular calcium concentration, and possesses anti-inflammatory and anti-cancer activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.02%
- No. CAS: 1383718-29-3
- Fòrmula: C27H39N3O9S3
- Peso molecular:645.81
-
Almacenamiento:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Calcium Channel Blocker Library
HY-L117
-
Heterocyclic Compound Library
HY-L138
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) NecroX-5
More
Customer Validation & Images
-
WB
Ver todos los productos específicos de isoformas Calcium Channel
More
Actividad biológica
Calcium channel[1]
NecroX-5 (10 or 40 μM) inhibits breast cancer cell migration, which is correlated with mitoROS reduction, and mediated by AKT inhibition. NecroX-5 (10 μM) decreases intracellular calcium concentration in 4T1 cells by blocking Ca2+ influx, which mediated the inhibition of cell migration, AKT downregulation and the reduction of mitochondrial ROS levels[1]. NecroX-5 (10 μM) treatment for 24 h, effectively decreases the increased TNFα, TGFβ1, pSmad2 and the expression of Dcn in LPS-stimulated H9C2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1383718-29-3
-
Appearance Solid
-
Peso molecular 645.81
-
Fòrmula C27H39N3O9S3
-
Color Light brown to brown
-
SMILES
O=S1(CCN(CC2=CC3=C(NC(C4=CC=CC=C4)=C3)C(NCC5CCOCC5)=C2)CC1)=O.CS(=O)(O)=O.CS(=O)(O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Cytoprotective Mechanism of Necrox-5 Against Toxicity Induced by Experimental Ferroptosis Instigators and the Pesticide Propargite. [Abstract]2026 Feb 12;27(4):1772. PMID: 41751908 -
Int Immunopharmacol
NecroX-5 alleviate lipopolysaccharide-induced acute respiratory distress syndrome by inhibiting TXNIP/NLRP3 and NF-κB. [Abstract]2020 Apr;81:106257. PMID: 32044659
NecroX-5 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2020 Apr;81:106257. [Abstract]
NecroX-5 inhibits the NLRP3 inflammasome activation in macrophages. RAW264.7 cells are firstly pretreated with 20 μM NecroX-5 for 1 h and then stimulated with LPS (1 μg/mL) for 8 h followed by 5 mmol/L of ATP for 30 min. Quantification of western blot in panen D.
-
FEBS J
Propionibacterium acnes evades microbicidal phagocytosis by inhibiting the mitochondrial biogenesis of nucleus pulposus cells. [Abstract]2025 Sep 2. PMID: 40891515
Solvente y solubilidad
DMSO : 170 mg/mL (263.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.83 mg/mL (4.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (28.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.83 mg/mL (4.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (28.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Park JH, et al. NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. Int J Oncol. 2017 Jan;50(1):185-192. [Content Brief]
[2]. Thu VT, et al. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts. Korean J Physiol Pharmacol. 2016 May;20(3):305-14. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5484 mL | 7.7422 mL | 15.4844 mL | 38.7111 mL |
| 5 mM | 0.3097 mL | 1.5484 mL | 3.0969 mL | 7.7422 mL | |
| 10 mM | 0.1548 mL | 0.7742 mL | 1.5484 mL | 3.8711 mL | |
| 15 mM | 0.1032 mL | 0.5161 mL | 1.0323 mL | 2.5807 mL | |
| 20 mM | 0.0774 mL | 0.3871 mL | 0.7742 mL | 1.9356 mL | |
| 25 mM | 0.0619 mL | 0.3097 mL | 0.6194 mL | 1.5484 mL | |
| 30 mM | 0.0516 mL | 0.2581 mL | 0.5161 mL | 1.2904 mL | |
| 40 mM | 0.0387 mL | 0.1936 mL | 0.3871 mL | 0.9678 mL | |
| 50 mM | 0.0310 mL | 0.1548 mL | 0.3097 mL | 0.7742 mL | |
| 60 mM | 0.0258 mL | 0.1290 mL | 0.2581 mL | 0.6452 mL | |
| 80 mM | 0.0194 mL | 0.0968 mL | 0.1936 mL | 0.4839 mL | |
| 100 mM | 0.0155 mL | 0.0774 mL | 0.1548 mL | 0.3871 mL |
NecroX-5 Related Classifications
HY-104015 Related Classifications
Powered by Bioz